These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation. Eckhardt K, Li S, Ammon S, Schänzle G, Mikus G, Eichelbaum M. Pain; 1998 May; 76(1-2):27-33. PubMed ID: 9696456 [Abstract] [Full Text] [Related]
8. Impact of environmental and genetic factors on codeine analgesia. Desmeules J, Gascon MP, Dayer P, Magistris M. Eur J Clin Pharmacol; 1991 May; 41(1):23-6. PubMed ID: 1782973 [Abstract] [Full Text] [Related]
9. O-demethylation of codeine to morphine inhibited by low-dose levomepromazine. Vevelstad M, Pettersen S, Tallaksen C, Brørs O. Eur J Clin Pharmacol; 2009 Aug; 65(8):795-801. PubMed ID: 19308365 [Abstract] [Full Text] [Related]
11. Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI). Dayer P, Desmeules J, Leemann T, Striberni R. Biochem Biophys Res Commun; 1988 Apr 15; 152(1):411-6. PubMed ID: 3358767 [Abstract] [Full Text] [Related]
12. Are poor metabolisers of sparteine/debrisoquine less pain tolerant than extensive metabolisers? Sindrup SH, Poulsen L, Brøsen K, Arendt-Nielsen L, Gram LF. Pain; 1993 Jun 15; 53(3):335-339. PubMed ID: 8351162 [Abstract] [Full Text] [Related]
15. Selective effects of somatostatin analogs on human drug-metabolizing enzymes. Rasmussen E, Eriksson B, Oberg K, Bondesson U, Rane A. Clin Pharmacol Ther; 1998 Aug 15; 64(2):150-9. PubMed ID: 9728895 [Abstract] [Full Text] [Related]
16. Impact of ethnic origin and quinidine coadministration on codeine's disposition and pharmacodynamic effects. Caraco Y, Sheller J, Wood AJ. J Pharmacol Exp Ther; 1999 Jul 15; 290(1):413-22. PubMed ID: 10381807 [Abstract] [Full Text] [Related]
17. Lack of relationship between quinidine pharmacokinetics and the sparteine oxidation polymorphism. Nielsen F, Rosholm JU, Brøsen K. Eur J Clin Pharmacol; 1995 Jul 15; 48(6):501-4. PubMed ID: 8582470 [Abstract] [Full Text] [Related]
18. Pharmacogenetic determination of the effects of codeine and prediction of drug interactions. Caraco Y, Sheller J, Wood AJ. J Pharmacol Exp Ther; 1996 Sep 15; 278(3):1165-74. PubMed ID: 8819499 [Abstract] [Full Text] [Related]
19. Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine. Sindrup SH, Brøsen K, Bjerring P, Arendt-Nielsen L, Larsen U, Angelo HR, Gram LF. Clin Pharmacol Ther; 1990 Dec 15; 48(6):686-93. PubMed ID: 2249379 [Abstract] [Full Text] [Related]
20. Can extremely low or high morphine formation from codeine be predicted prior to therapy initiation? Lötsch J, Rohrbacher M, Schmidt H, Doehring A, Brockmöller J, Geisslinger G. Pain; 2009 Jul 15; 144(1-2):119-24. PubMed ID: 19395173 [Abstract] [Full Text] [Related] Page: [Next] [New Search]